A world eager for progress on vaccines to guard against the SARS-CoV-2 coronavirus and/or COVID-19 might have to wait a bit longer for a breakthrough. The CEO of Moderna (NASDAQ:MRNA), the developer of what many experts consider the leading vaccine candidate, said Friday that his company is slowing enrollment in its crucial phase 3 clinical trial.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,